Abstract:Pharmacometric approaches achieves higher power to detect a drug effect compared to traditional statistical hypothesis tests. Known drawbacks come from the model building process where multiple testing and model misspecification are major causes for type I error inflation. IMA is a new approach using mixture models and the likelihood ratio test (LRT) to test for drug effect. It previously showed type I error control and unbiased drug estimates in the context of two-arms balanced designs using real placebo data, in comparison to the standard approach (STD). The aim of this study was to extend the assessment of IMA and STD regarding type I error, power, and bias in the drug effect estimates under various types of model misspecification, with or without LRT calibration. Two classical statistical approaches, t-test and Mixed-Effect Model Repeated Measure (MMRM), were also added to the comparison. The focus was a simulation study where the extent of the model misspecification is known, using a response model with or without drug effect as motivating example in two sample size scenarios. The IMA performances were overall not impacted by the sample size or the LRT calibration, contrary to STD which had better type I error results with the larger sample size and calibrated LRT. In terms of power STD required LRT calibration to outperform IMA. T-test and MMRM had both controlled type I error. The t-test had a lower power than both STD and IMA while MMRM had power predictions similar to IMA. IMA and STD had similarly unbiased drug effect estimates, with few exceptions. IMA showed again encouraging performances (type I error control and unbiased drug estimates) and presented reasonable power predictions. The IMA performances were overall more robust towards model mis-specification compared to STD. IMA confirmed its status of promising NLMEM-based approach for hypothesis testing of the drug effect and could be used in the future, after further evaluations, as primary analysis in confirmatory trials.

Modeling Schizophrenic Behavior and Testing Drug Efficacy Using General Mixture Components

Modeling Schizophrenic Behavior Using General Mixture Components.

Modeling schizophrenic behavior using general mixture components

The Analysis of Repeated-Measures Data on Schizophrenic Reaction Times Using Mixture Models.

Finding the "genuine" Schizotype: A Model and Method for Resolving Heterogeneity in Performance on Laboratory Measures in Experimental Psychopathology Research

Finding the" genuine" schizotype: A model and method for resolving heterogeneity in performance on laboratory research.

Effects of Randomness in the Development of Machine Learning Models in Neuroimaging Studies of Schizophrenia

Using normative modeling to assess pharmacological treatment effect on brain state in patients with schizophrenia

Model-based optimal randomization procedure for treatment–covariate interaction tests

Assessment of non-linear mixed effects model-based approaches to test for drug effect using simulated data: type I error and power properties

Permutation tests for detecting and estimating mixtures in task performance within groups.

The analysis of repeated‐measures data on schizophrenic reaction times using mixture models

Evaluating the Validity of Post-Hoc Subgroup Inferences: A Case Study

A comparison of methods for the analysis of binomial proportion data in behavioral research

A comparison of methods for model selection when estimating individual treatment effects

An Empirical Comparison of Parametric and Permutation Tests for Regression Analysis of Randomized Experiments

A Bayesian Approach to Reducing Heterogeneity in Laboratory Measures: An Illustration from Schizophrenia Research

Some Statistical Issues of Confirming Efficacy in Clinical Trials

Permutation Tests for Assessing Potential Non-Linear Associations between Treatment Use and Multivariate Clinical Outcomes

Power Analysis for Cluster Randomized Trials with Binary Outcomes Modeled by Generalized Linear Mixed-Effects Models

Resolving the latent structure of schizophrenia endophenotypes using expectation-maximization-based finite mixture modeling.